



PATENT CASE CV01489K

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED  
MAY 30 2003  
TECH CENTER 160A2900

-----X  
In re Application of:  
Harry R. Davis et al

For Patent For:  
Combinations of Peroxisome Proliferator-  
Activated Receptor (PPAR) Activator(s) and  
Sterol Absorption Inhibitor(s) and  
Treatments for Vascular Indications

Examiner: To Be Assigned

Art Unit: 1619

Serial No.: 10/057,323

Filing Date: January 25, 2002

-----X  
Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

It is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. A copy of each cited document is attached.

A copy of the PCT International Search Report dated April 23, 2003 for corresponding PCT Application No. PCT/US02/02009 is submitted for the Examiner's review.

No fee is believed to be due, however, if any fee is due the Commissioner is authorized to charge Deposit Account Number 19-0365 for any fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


on May 22, 2003

**Ann Marie Cannoni**  
Registered Representative

  
Signature

5/22/03  
Date

Respectfully submitted,

  
Ann Marie Cannoni  
Reg. No. 35,972  
Attorney for Applicants  
(908) 298-5024

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.: <b>CV01489K</b> APPLICANT: <b>Harry R. Davis, et al.</b> FILING DATE: <b>01/25/2002</b>		SERIAL NO.: <b>10/057,323</b> GROUP: <b>1619</b>				
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	AL	WO 99/08501	2/25/99	PCT				
	AM							
	AN							
	AO							
	AP							
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
	AQ	"Study showed ezetimibe significantly reduced levels of LDL cholesterol or "bad" cholesterol in patients" <i>Schering Press Release</i> 1-3 (2001)						
	AR	Kosoglou <i>et al.</i> , "Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe" <i>Atherosclerosis</i> (2):3(2001)						
	AS	Davis <i>et al.</i> , "The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs" <i>Metabolism</i> 50(10):1234-1241(2001)						
	AT							
	AU							
	AV							
EXAMINER				DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								